A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

ID Number 16-1508

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to find out whether an investigational drug called CPI-444 can be used, on its own, or in combination with another investigational drug called atezolizumab in subjects with the specific type of cancer you have.

The purpose of this clinical trial is to find out the best dose of CPI-444, on it's own and in combination with atezolizumab and to learn what effects CPI-444 on its own or in combination with atezolizumab has on individuals and their cancer.

Contact Information
Dana Ostrowski
(212) 824-7309

Recruiting Patients: Yes